Australia markets closed

Alector Inc. Registered Shares (0Z2.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
16.70-1.90 (-10.22%)
At close: 9:57PM CET
Full screen
Previous close18.60
Open18.50
Bid16.70 x 0
Ask18.60 x 0
Day's range16.70 - 18.50
52-week range16.70 - 18.50
Volume0
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Alector Presents Encouraging New AL001 Data from the Symptomatic FTD-GRN Cohort of INFRONT-2 Phase 2 Open-label Clinical Study

    Progranulin Levels Increase to Normal Ranges Multiple Biomarkers of Disease Showed Improvement from Baseline with AL001 Treatment, Including GFAP, a Prognostic Marker for FTD Associated with Brain Atrophy FTD-GRN Patients Showed a Slowing of Clinical Progression with AL001 Treatment Relative to GENFI2 Matched Control Cohort Data from Phase 2 Study Presented at Clinical Trials of Alzheimer Disease Conference; Management to Host Webcast to Review Results Today at 4:00 p.m. ET BOSTON, Nov. 12, 2021

  • GlobeNewswire

    Alector Presents Preclinical Data from AL009 Multi-Siglec Inhibitor Program at the Society for Immunotherapy of Cancer’s 36th Annual Meeting

    Preclinical Oncology Program Highlights Alector’s Expertise in Harnessing Components of the Innate Immune System to Impact Disease AL009 Targets Innate Immune Checkpoint Receptors, Blocks Immune Suppression of Tumor Cells and Activates Potent Anti-Cancer Immune Response WASHINGTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented preclinical data from its AL009 immuno-oncology program in poster at the So

  • GlobeNewswire

    Alector Presents New Data from Multiple Pipeline Programs at 2021 CTAD Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, shared data from its AL003 and AL101 programs in poster presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference being held November 9-12, 2021, virtually and in Boston. “Since our formation, Alector has established a deep pipeline of therapeutic immuno-neurology candidates, each of which aims to harness the bod